Exousia Bio, Inc.

LMMYdata completeness 75%3 fiscal years on file

Data notes: no data for concept 'capex'; no data for concept 'totalDebt'; no data for concept 'interestExpense'

i. The business — what you’d actually own

Figure	FY 2023	FY 2024	FY 2025
Revenue	$0¹	$11,500²	$3,750²
Net income	−$56,421³	−$25,807⁴	$51,395⁴
Operating cash flow	−$38,111⁵	−$12,484⁶	−$4,528⁶
Capital expenditure	—	—	—
Free cash flow (derived)	—	—	—
Total debt	—	—	—
Cash & equivalents	$7,855⁷	$1,028⁸	$0⁸
Diluted shares	5.7M	7.8M	7.8M

Superscripts are receipts. Each links to the SEC filing the number came from (full list at the bottom).

ii. Your slice — ownership made literal

If you owned

Net assets behind them

your share of equity

Profit it earned you last year

$0.07

Free cash flow it threw off

—

Debt you’d be carrying

—

10 shares is a claim on $0 of net worth that earned you $0.07 last year.

iii. Is this a good business?

Moat signal · return on equity

— avg · 3y

Not enough data in the filings for a return-on-capital reading.

Management signal · capital allocation

+37% shares · 3y

Share count is up 37% over 3 years — owners have been diluted. Worth asking what they got for it.

Signals, not verdicts — read from the filings above. Numbers don’t prove a moat; they show its footprint. You decide.

iv. What it’s worth — engine v0.1.0

DCF · Growth Exit 10Y

not applicable

only 0 years of FCF (need ≥3) — model not applicable

DCF · Growth Exit 5Y

not applicable

only 0 years of FCF (need ≥3) — model not applicable

Earnings Power Value

not applicable

normalized (5y-median) earnings non-positive — EPV undefined

Graham Number

not applicable

diluted EPS missing or non-positive — Graham Number undefined

Different models answer different questions — which to trust when →

Sources — the receipts